Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

NCT07615101 is registered in ClinicalTrials.gov with Norroy Bioscience Co., LTD as lead sponsor.

NCT NCT07615101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07615101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Lead sponsor
Norroy Bioscience Co., LTD
Phase
Phase 3
Overall status
Recruiting
Start date
August 6, 2026
Completion date
July 30, 2027
Enrollment
365 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer (diagnosis)